TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner

Abstract
The HIV-1 capsid protein makes up the core of the virion and plays a critical role in early steps of HIV replication. Due to its exposure in the cytoplasm after entry, HIV capsid is a target for host cell factors that act directly to block infection such as TRIM5α and MxB. Several host proteins also play a role in facilitating infection, including in the protection of HIV-1 capsid from recognition by host cell restriction factors. Through an unbiased screening approach, called HIV-CRISPR, we show that the CPSF6-binding deficient, N74D HIV-1 capsid mutant is sensitive to restriction mediated by human TRIM34, a close paralog of the well-characterized HIV restriction factor TRIM5α. This restriction occurs at the step of reverse transcription, is independent of interferon stimulation, and limits HIV-1 infection in key target cells of HIV infection including CD4+ T cells and monocyte-derived dendritic cells. TRIM34 can also restrict some SIV capsids. TRIM34 restriction requires TRIM5α as knockout or knockdown of TRIM5α results in a loss of antiviral activity. Through immunofluorescence studies, we show that TRIM34 and TRIM5α colocalize to cytoplasmic bodies and are more frequently observed to be associated with infecting N74D capsids than with WT HIV-1 capsids. Our results identify TRIM34 as an HIV-1 CA-targeting restriction factor and highlight the potential role for heteromultimeric TRIM interactions in contributing to restriction of HIV-1 infection in human cells. HIV-1 infection in humans is the result of cross-species transmission of a related primate lentivirus from chimpanzees. In order to adapt to replicate in human cells, HIV-1 adapted to host proteins that restrict infection by viruses. The HIV-1 capsid protein encapsidates the HIV-1 genome, allowing it to be delivered to the host cell for integration into the host chromosome. However, on delivery to the cytoplasm the HIV-1 capsid protein is exposed to an array of capsid-targeting restriction factors that act to limit infection. Viral mutants can be used to reveal some of these restriction factors. Our results show that TRIM34 is an antiviral effector that blocks infection of an HIV with a particular mutation in capsid. TRIM34 also inhibits some lentiviruses that infect monkeys. This block requires the closely-related paralog TRIM5α, a capsid-targeting restriction factor with well-characterized antiviral activity in primates. These results highlight the complex interaction between HIV-1 with human antiviral proteins.
Funding Information
  • National Institute of Allergy and Infectious Diseases (R01 AI147877)
  • Center for AIDS Research, University of Washington (AI027757)
  • National Institute of Allergy and Infectious Diseases (R01 AI30927)
  • National Institute of Allergy and Infectious Diseases (R37 AI147868)
  • National Institute of Allergy and Infectious Diseases (R01 AI093258)